title: Bevacizumab local complications.
authors.forename: Maximiliano
authors.initials: M
authors.lastname: Gordon-Angelozzi
authors.forename: Raul
authors.initials: R
authors.lastname: Velez-Montoya
authors.forename: Jans
authors.initials: J
authors.lastname: Fromow-Guerra
authors.forename: Gerardo
authors.initials: G
authors.lastname: García-Aguirre
authors.forename: Jose Luis
authors.initials: JL
authors.lastname: Guerrero-Naranjo
authors.forename: Hugo
authors.initials: H
authors.lastname: Quiroz-Mercado
authors.forename: Virgilio
authors.initials: V
authors.lastname: Morales-Cantón
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D020256:Choroidal Neovascularization / Q000188:drug therapy; D003930:Diabetic Retinopathy / Q000188:drug therapy; D005128:Eye Diseases / Q000139:chemically induced* / Q000175:diagnosis; D005260:Female; D005451:Fluorescein Angiography; D006801:Humans; D007267:Injections; D008268:Macular Degeneration / Q000188:drug therapy; D008269:Macular Edema / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D014463:Ultrasonography; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014822:Vitreous Body; D055815:Young Adult
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab